Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

15.39 +0.16 (+1.05%)
Streaming Delayed Price Updated: 1:06 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,223
Open 15.27
Bid (Size) 15.38 (2)
Ask (Size) 15.41 (4)
Prev. Close 15.23
Today's Range 15.13 - 15.75
52wk Range 12.95 - 25.47
Shares Outstanding 75,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
From Arcus Biosciences
Via Business Wire

Performance

YTD
-21.80%
-21.80%
1 Month
-16.72%
-16.72%
3 Month
-2.10%
-2.10%
6 Month
-2.04%
-2.04%
1 Year
-16.54%
-16.54%

More News

Read More
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Navigating 5 Analyst Ratings For Arcus Biosciences
Via Benzinga
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
Recap: Arcus Biosciences Q4 Earnings
Via Benzinga
Earnings Scheduled For February 21, 2024
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Preview: Arcus Biosciences's Earnings
Via Benzinga
Key Takeaways From Arcus Biosciences Analyst Ratings
Via Benzinga
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Via Benzinga
Gilead and Arcus Announce Amended Collaboration and Equity Investment
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.